The intense interest surrounding glucagon-like peptide-1 (GLP-1) and other incretin-based medications is impossible to ignore. They have received significant public and media attention due to their potential implications for obesity and related conditions. Some commentators have touted them as “everything drugs” that will rewrite the trajectory of human mortality and reverse stagnating life expectancy trends.…
